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Abstract
 
Screening of serum by using a surface plasmon resonance
 
analysis assay identified 
 
b
 
2
 
-glycoprotein-I/apolipoprotein H as
a plasma component binding to the renal epithelial endocy-
tic receptor megalin. A calcium-dependent megalin-medi-
ated 
 
b
 
2
 
-glycoprotein-I endocytosis was subsequently demon-
strated by ligand blotting of rabbit renal cortex and uptake
analysis in megalin-expressing cells. Immunohistochemical
and immunoelectron microscopic examination of kidneys
and the presence of high concentrations of 
 
b
 
2
 
-glycoprotein-I
in urine of mice with disrupted megalin gene established
that megalin is the renal clearance receptor for 
 
b
 
2
 
-glycopro-
tein-I. A significant increase in functional affinity for puri-
fied megalin was observed when 
 
b
 
2
 
-glycoprotein-I was bound
to the acidic phospholipids, phosphatidylserine and cardio-
lipin. The binding of 
 
b
 
2
 
-glycoprotein-I and 
 
b
 
2
 
-glycoprotein-I–
phospholipid complexes to megalin was completely blocked
by receptor-associated protein.
In conclusion, we have demonstrated a novel receptor
recognition feature of 
 
b
 
2
 
-glycoprotein-I. In addition to ex-
plaining the high urinary excretion of 
 
b
 
2
 
-glycoprotein-I in
patients with renal tubule failure, the data provide mo-
lecular evidence for the suggested function of 
 
b
 
2
 
-glycopro-
tein-I as a linking molecule mediating cellular recognition
 
of phosphatidylserine-exposing particles. (
 
J. Clin. Invest.
 
1998. 102:902–909.) Key words: 
 
b
 
2
 
-glycoprotein-I 
 
•
 
 apolipo-
protein H 
 
•
 
 megalin 
 
•
 
 phosphatidylserine 
 
•
 
 Fanconi syn-
drome
 
Introduction
 
b
 
2
 
-glycoprotein-I (
 
b
 
2
 
gpI)
 
1
 
 is a predominant plasma protein
(0.2 mg/ml) of 50 kD consisting of five short consensus repeat/
Sushi modules. 30% of 
 
b
 
2
 
gpI in plasma is associated with lipo-
protein particles, probably due to its binding to acidic phos-
pholipids, e.g., phosphatidylserine (PS) (1, 2). Therefore, 
 
b
 
2
 
gpI
is also designated as apolipoprotein H in the literature (3, 4).
The function of 
 
b
 
2
 
gpI is not fully elucidated, but via bind-
ing of PS it is suggested to regulate platelet-dependent throm-
bosis as well as the clearance of liposomes, PS-expressing cells,
and foreign particles (5–7). A substantial interest has also been
attributed to pathological properties of 
 
b
 
2
 
gpI. One aspect is
the presence of antiphospholipid antibodies in plasma of pa-
tients with antiphospholipid syndrome and other autoimmune
diseases (8, 9). In fact, recent reports indicate that most of the
antiphospholipid antibodies do not bind to phospholipids, but
instead bind to 
 
b
 
2
 
gpI when it is in complex with the acidic
phospholipids PS and cardiolipin or immobilized on negatively
charged surfaces (10, 11). Another pathological aspect of 
 
b
 
2
 
gpI
relates to the high urinary excretion of the protein in patients
with Fanconi-type renal tubular failure (12). Accordingly,
 
b
 
2
 
gpI is a superior marker of this disease (12).
This study was initiated in order to identify novel renal-fil-
tered plasma ligands for megalin (13, 14), an endocytic recep-
tor expressed in various absorptive epithelia including kidney,
yolk sac, lung, and the ependyma of the central nervous system
(15–17). In kidney, a very high megalin expression is seen in
renal proximal tubules (18), where megalin has been demon-
strated to mediate uptake of glomerular-filtered polybasic
drugs (19) and vitamin B
 
12
 
-transcobalamin (20). Several high
molecular weight proteins including apolipoprotein B (21),
apolipoprotein E (22), and clusterin (23) are also reported to
bind to megalin in vitro, but due to the glomerular filtration
barrier their recognition by megalin may occur predominantly
in extrarenal tissues and in glomerular podocytes (24).
A surface plasmon resonance (SPR) analysis screening
procedure of fractionated serum led to the identification of
 
b
 
2
 
gpI as a novel megalin ligand. The physiological relevance of
this observation was validated by a number of studies includ-
ing uptake analysis in megalin-expressing cells, determination
of the renal fate of 
 
b
 
2
 
gpI in mice with disrupted megalin gene,
and evaluation of the effect of acidic phospholipids on the
binding of 
 
b
 
2
 
gpI to megalin.
 
Methods
 
Receptors, ligands, and antibodies.
 
Megalin was purified by receptor-
associated protein (RAP) affinity chromatography of renal cortex
membranes (25). Low density lipoprotein receptor–related protein
was purified by 
 
a
 
2
 
-macroglobulin affinity chromatography of solubi-
lized human placenta membranes (26). Human RAP was a recombi-
nant protein produced in 
 
Escherichia coli
 
. 
 
b
 
2
 
gpI was purified from
human plasma as described (27). Iodination was performed by the
 
chloramine T method (28). The specific activity was 
 
z
 
 1 MBq/
 
m
 
g.
The phospholipids were from Sigma Chemical Co. (St. Louis, MO)
and homogenized by sonication before use essentially as described
previously (27). Two rabbit polyclonal antibodies against human
 
b
 
2
 
gpI were used, one purchased from PerImmune Inc. (Rockville,
MD) and another characterized previously (29). The latter antibody
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was affinity-purified on a 
 
b
 
2
 
gpI column. A monoclonal antibody 5B-
B11 raised against rabbit megalin (30) and a sheep polyclonal IgG
raised against rat megalin (20) have been described previously.
 
Gel filtration and ion exchange chromatography.
 
2 ml of rabbit
serum was loaded onto a 175-ml Superdex-200 (Pharmacia Biotech
AB, Uppsala, Sweden) column using 10 mM Hepes, 150 mM NaCl,
and 1.5 mM CaCl
 
2
 
, 1 mM EGTA, pH 7.4, as running buffer. Cation
exchange chromatography was carried out on a 10-ml Mono S (Phar-
macia Biotech AB) FPLC column and bound proteins were eluted
with a linear gradient of 0–1 M NaCl in 20 mM Tris, pH 7.
 
Gel electrophoresis, protein sequence analysis, and ligand blot-
ting.
 
Protein was electroblotted from a 4–16% polyacrylamide SDS
gel onto a polyvinylidene difluoride membrane (Problot; Applied
Biosystems, Inc., Foster City, CA). The electroblotted protein was
cut out and subjected to Edmann degradation using an Applied Bio-
systems 477 A sequencer equipped with a 120 A online chromato-
graph. Ligand blotting was essentially carried out as described (25).
 
SPR analysis.
 
For the SPR analyses, the BIAcore sensor chips
(type CM5; Biosensor, Uppsala, Sweden) were activated with a 1:1
mixture of 0.2 M 
 
N
 
-ethyl-
 
N
 
9
 
-(3-dimethylaminopropyl) carbodiimide
and 0.05 M 
 
N
 
-hydroxysuccinimide in water according to the manufac-
turer. Rabbit renal megalin was immobilized as described (20). The
SPR signal from immobilized rabbit megalin generated 15–21 
 
3
 
 10
 
3
 
BIAcore response units (RU) equivalent to 25–35 fmol/mm
 
2
 
. The
flow cells were regenerated with 20 
 
m
 
l 1.5 M glycine-HCl, pH 3.0. The
flow buffer was 10 mM Hepes, 150 mM NaCl, and 1.5 mM CaCl
 
2
 
, 1 mM
EGTA,
 
 
 
pH 7.4. The binding data were analyzed using the BIA evalu-
ation program. The number of ligands bound per immobilized recep-
tor was estimated by dividing the ratio RU
 
ligand
 
/mass
 
ligand
 
 with RU
 
receptor
 
/
mass
 
receptor
 
.
 
Uptake of 
 
125
 
I-
 
b
 
2
 
gpI in rat yolk sac cells.
 
Megalin-expressing Brown
Norway rat yolk sac epithelial cells transformed with mouse sarcoma
virus (31) were grown to confluence (
 
z 
 
300,000 cells/well) in 24-well
plates (Nunc A/S, Roskilde, Denmark) in MEM (Gibco, Paisley, UK)
containing 10% FCS. Incubation with 
 
125
 
I-
 
b
 
2
 
gpI
 
 
 
was carried out in
MEM supplemented with 0.1% BSA. Degradation of the proteins
was measured by precipitation of the incubation medium in 12.5%
trichloroacetic acid. Cell-associated radioactivity was measured after
three 5-min washes of the cells with ice-cold 20 mM EDTA in PBS in
order to dissociate calcium-dependent surface-associated ligand. Ra-
dioactivity was subsequently counted in the cells released by trypsiniza-
tion. Chloroquine and leupeptin (both from Sigma Chemical Co.)
were used as inhibitors of lysosomal enzyme activity.
 
Analysis of megalin gene knockout mice.
 
Mice genetically defi-
cient for megalin were generated by gene targeting as described pre-
viously (32). Although most megalin 
 
2
 
/
 
2
 
 mice die perinatally, 
 
z
 
 2%
of the animals survive to adulthood (Nykjaer, A., H. Vorum, D. Dra-
gun, D. Walther, C. Jacobsen, J. Herz, F. Melsen, E.I. Christensen,
and T.E. Willnow, manuscript submitted for publication). For urine
collection, these adult megalin knockout mice and control littermates
were placed in metabolic cages for 1 h and given 10% sucrose in
drinking water. Urine samples were collected on ice and were qualita-
tively indistinguishable from samples obtained without sucrose load.
Creatinine and protein concentrations as well as total urine volume
per hour were similar in knockout mice and control animals, indicat-
ing normal glomerular filtration rates in receptor-deficient kidneys.
 
Preparation of renal tissue.
 
Normal human renal tissue was ob-
tained from resected renal carcinoma kidneys and fixed in 8%
paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.2. Kid-
neys from megalin-deficient and control mice were fixed by perfusion
through the heart with 4% paraformaldehyde in the same buffer. Rat
kidneys were fixed by retrograde perfusion through the abdominal
aorta with 1% paraformaldehyde. The tissues were trimmed into
small blocks, further fixed by immersion for 1 h in 1% paraformalde-
hyde, infiltrated with 2.3 M sucrose containing 2% paraformaldehyde
for 30 min and frozen in liquid nitrogen.
 
Immunocytochemistry.
 
For light microscopy, 0.8-
 
m
 
m cryosections
were obtained at 
 
2
 
80
 
8
 
C with an FCS Reichert Ultracut S cryoultra-
Figure 1. (A) SPR analysis of megalin binding activity in fractions of 
rabbit serum. Rabbit serum was loaded on a Superdex-200 column 
using an isotonic Hepes-NaCl-CaCl2 buffer as running buffer. 2-ml 
fractions were collected and each was subjected to SPR analysis on a 
flow cell sensor chip with immobilized rabbit megalin and a control 
chip with no megalin. The continuous curve shows the A280 profile of 
eluted proteins and the discontinuous curve (filled circles) represents 
the mass-equivalent response units (RU) on the megalin sensor chip 
after subtraction of the nonspecific response on a blank chip. (B) Cat-
ion exchange chromatography of fractions 38–42 displayed in A. The 
panel shows the elution profile and the SDS gel electrophoresis of a 
50-kD protein eluting at a high salt concentration. The amino-termi-
nal sequence of the 50-kD protein is displayed. (C) SPR analysis of 
the binding of purified human b2gpI (10 mg/ml) to immobilized mega-
lin. The first arrow on the sensorgram indicates the start of injection 
with binding buffer plus ligand. The second arrow demonstrates the 
start of the dissociation phase by flow with binding buffer alone.
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purified rabbit megalin (Fig. 1 
 
A
 
). A peak in binding activity
was seen in fractions 38–42 and a smaller peak in fraction 50–
54. SDS-PAGE of the fractions showed a wide spectrum of
proteins of 20–150 kD in the high peak and 67 kD and less in
the smaller peak (not shown). Cation exchange (Fig. 1 
 
B
 
)
chromatography of fractions of the two peaks showed that one
predominant 50 kD protein from the high peak fraction was
strongly bound to the cation exchange matrix. The fraction
containing this protein exhibited megalin-binding activity, and
amino-terminal sequencing of the electroblotted 50-kD rabbit
protein yielded the sequence Tyr-Arg-Thr-X-Pro-Lys-Asp-
Figure 2. Ligand blot-
ting with 125I-b2gpI. Tri-
ton X-100–solubilized 
rabbit renal cortex 
membranes (z 500 mg/
lane) were electroblot-
ted from 4–16% SDS-
polyacrylamide gels 
(nonreducing condi-
tions) and incubated 
with 125I-b2gpI in the ab-
sence (lane 1) or pres-
ence of 10 mM EDTA 
(lane 2) or 1 mM RAP 
(lane 3). The ligand 
blots were incubated 
with 35,000 Bq 125I-
ligand/ml at 48C for 20 h 
and exposed on Amer-
sham Hyperfilm at 2708C for 72 h. Lane 4 is an antimegalin immuno-
blot of the same blot as in lane 1 after it had been subjected to ligand 
blotting and autoradiography. The primary antibody is monoclonal 
antibody 5B-B11 recognizing rabbit megalin (30). Alkaline phos-
phatase–conjugated anti–mouse IgG was used as secondary antibody.
 
microtome. For electron microscopy, ultrathin (70–90 nm) sections
were cut at 
 
2
 
100
 
8
 
C. For immunolabeling, the sections were incu-
bated with affinity-purified primary antibody, 1 
 
m
 
g/ml either at room
temperature for 1 h, or overnight at 4
 
8
 
C after preincubation in PBS
containing 0.05 M glycine and 1% BSA. For light microscopy, the sec-
tions were subsequently incubated with peroxidase-conjugated sec-
ondary antibodies (Dako A/S, Glostrup, Denmark). The peroxidase
was visualized with diaminobenzidine and the sections were subse-
quently counterstained with Meier’s stain for 2 min and examined in
a Leica DMR microscope equipped with a Sony SCCD color video
camera attached to a Sony Digital Still recorder. For electron micros-
copy, 10-nm goat anti–rabbit gold particles (BioCell, Cardiff, UK)
were incubated with the sections subsequent to the incubation with
primary antibody. The sections were embedded in 2% methylcellu-
lose containing 0.3% uranyl acetate and studied in a Phillips CM100
electron microscope. For control, sections were incubated with sec-
ondary antibodies alone or with nonspecific rabbit IgG. None of the
controls showed any labeling.
 
Results
 
Identification of b2gpI as a megalin ligand. The screening strat-
egy used here for identifying filtered ligands in plasma was
based on the facts that small and cationic molecules preferen-
tially are filtered in the glomerulus and that cationic features
of megalin ligands are important for recognizing megalin (19)
on the apical surface of the proximal tubules (18). Initially,
SPR analysis measured megalin binding activity in serum frac-
tionated by gel filtration. Subsequently, the proteins in the
most binding-active fractions were further separated by cation
exchange chromatography. Fig. 1 shows rabbit serum fraction-
ated by gel filtration on a Superdex-200 column and the SPR
signal of each fraction applied to a flow cell with immobilized
Figure 3. Uptake and degradation of 125I-b2gpI in the rat yolk sac car-
cinoma cell line, BN/MSV. (A) Time courses for uptake (filled cir-
cles) and degradation (open circles). Confluent cell layers (300,000 
cells/well) in 24-well plates were incubated with 125I-b2gpI (400 Bq 5 
8 fmol). Degradation was measured as the increase in trichloroacidic-
soluble radioactivity in the medium. Uptake was measured as the 
cell-associated radioactivity plus the degraded fraction. The uptake/
degradation rate of the 125I-b2gpI was 15% (z 1 fmol) per hour. 
(B) The inhibitory effect on uptake and degradation by leupeptin 
(100 mM), chloroquine (100 mM), RAP (1 mM), anti–rat megalin IgG 
(100 mg/ml), and rat nonimmune IgG (100 mg/ml). All values are 
means of triplicates.
Figure 4. Immunochemical and immunoelectron microscopic detection of b2gpI in human, rat, and mouse renal cortex. (Four top panels) Light 
microscope immunohistochemical labeling for b2gpI using horseradish peroxidase, in proximal tubules from a human, a rat, a wild-type mouse 
(1/1), and a megalin-deficient mouse (2/2). Labeling is seen as a brown granular staining. The proximal tubules of the megalin-deficient 
mouse (2/2) did not show staining for b2gpI. (Bottom panel) Electron microscopic immunocytochemical labeling for b2gpI in a human renal 
proximal tubule using 10 nm colloidal gold coupled to goat anti–rabbit IgG. Gold particles are strongly accumulated in lysosomes.
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Asp-Leu. The SwissProt protein database identified the pro-
tein as the rabbit homologue of human b2gpI which has
Gly-Arg-Thr-Cys-Pro-Lys-Asp-Asp-Leu as the amino-termi-
nal sequence. Binding of b2gpI to megalin was subsequently
confirmed by SPR analysis of purified human b2gpI (Fig. 1 C).
This analysis estimated a Kd of 1.7 3 1027 M at 208C.
Megalin mediates endocytosis of b2gpI. Ligand blotting (Fig.
2) of rabbit renal cortex membranes with 125I-labeled b2gpI
identified megalin as the only b2gpI-binding protein in renal
cortex membrane. The binding was completely abolished by
the addition of EDTA (lane 2) or RAP (lane 3). Ligand blot-
ting to purified megalin revealed a similar staining (not
shown), whereas no significant binding to the homologous hu-
man LDL receptor–related protein was evident by ligand blot-
ting or SPR analysis (data not shown).
Endocytosis of 125I-b2gpI was studied (Fig. 3 A) in a rat yolk
sac epithelial cell line which exhibits a high expression of
megalin (31). 125I-labeled b2gpI was effectively taken up and
radioactive degradation products appeared in the medium af-
ter a lag time of z 20 min. The uptake was effectively inhibited
by RAP and a polyclonal antibody raised against megalin (Fig.
3 B).
Chloroquine, a weak membrane-diffusible base raising pH
in intracellular compartments, and leupeptin, a membrane-dif-
fusible proteinase inhibitor, were used to show that the degraded
ligand in the medium was accounted for by receptor-mediated
endocytosis and lysosomal degradation. Both reagents inhibit
lysosomal enzyme activity (33, 34) and, in addition, chloro-
quine is an inhibitor of membrane trafficking (34). In accor-
dance with these effects, leupeptin and chloroquine caused a
strong decrease in degradation of 125I-b2gpI leading to accumu-
lation of nondegraded radiolabel within the cells (Fig. 3 B).
Furthermore, cells incubated with chloroquine, but not those
incubated with leupeptin, exhibited a partial inhibition in
ligand uptake (Fig. 3 B) in agreement with the additional cellu-
lar effect of chloroquine.
b2gpI is excreted in the urine of megalin-deficient mice. To
determine whether megalin is the renal proximal tubule com-
ponent responsible for the uptake of b2gpI in the ultrafiltrate,
we investigated the renal content of b2gpI in the kidney cortex
of a human, a rat, and mice, including one with a disrupted
megalin gene. Light microscopic immunohistochemistry of
normal kidneys of the three species revealed a granular stain-
ing of b2gpI in renal proximal tubules (Fig. 4). The staining was
only observed in segment 1 of the proximal tubule, indicating
that the protein under physiological conditions is removed
very efficiently in the early part of the proximal tubule after
glomerular filtration. No other nephron segments showed any
immunoreactivity. Electron microscopic examination of im-
munogold-labeled kidney sections demonstrated that the gran-
ular staining was accounted for by staining of lysosomes. Fig. 4.
(bottom) shows the accumulation of gold particles in lyso-
somes of a human proximal tubule cell. In contrast to the stain-
ing in normal mice (Fig. 4, Mouse 1/1), there was virtually no
staining in kidneys of mice with disrupted megalin gene (Fig. 4,
Mouse 2/2).
In accordance with the kidney data, no b2gpI was detected
in the urine of normal mice, whereas the megalin-deficient
mice exhibited a high excretion as evaluated by immunoblot-
ting (Fig. 5 A). The urine from two myelomatosis patients suf-
fering from a Bence-Jones protein-induced Fanconi syndrome
(renal tubule failure) contained in accordance with previous
data (12, 35) also a significant content of b2gpI (Fig. 5 B).
Binding of PS to b2gpI increases the functional affinity for
megalin. The acidic phospholipids PS and cardiolipin bind
strongly to the basic region of the fifth SCP repeat of b2gpI
(36) and an SPR analysis was therefore performed to study the
effect of phospholipids on the binding of b2gpI to megalin. A
strong increase in the SPR signal was seen (Fig. 6 A), when PS
and cardiolipin were added to b2gpI, whereas no effect of the
neutral phosphatic acid and phosphatidylcholine was observed
(Fig. 6 B). A decreased dissociation rate of the b2gpI–PS com-
plexes (koff 5 1.33 3 1023 s21) compared with native b2gpI (koff 5
4.75 3 1023 s21) demonstrated a higher functional affinity of li-
posome-bound b2gpI. An exact Kd for the interaction of the
phospholipid-bound b2gpI to megalin was not measurable by
SPR due to the fact that the binding of several b2gpI molecules
per liposome may cause multisite interactions and different
size of the particles.
Concentration dependence of the binding of b2gpI–PS to
megalin. The maximum PS-augmented binding was seen
when b2gpI (10 mg/ml) was added to z 10 mg/ml PS. The bind-
ing of b2gpI to megalin (Fig. 7 A) was reduced at higher con-
centrations of PS, indicating that diluting the density of b2gpI
Figure 5. Urinary excretion of 
b2gpI in megalin-deficient mice 
and patients with Fanconi syn-
drome. (A) Analysis of urine from 
megalin 2/2 and control mice. 15 
ml of urine from mice either wild-
type (1/1, lanes 1, 4, and 5), het-
erozygous (1/2, lane 3), or ho-
mozygous for a disruption of the 
megalin gene (2/2, lanes 2, 6, and 
7) was subjected to 4–15% nonre-
ducing SDS-PAGE and subse-
quent immunoblot analysis using 
rabbit anti–human b2gpI poly-
clonal antibody and the enhanced 
chemiluminescence system (Am-
ersham, Arlington Heights, IL). 1 
mg purified human b2gpI (lane 8) was used as control. (B) Analysis of human urine samples. 0.5 ml of midstream urine samples from two individ-
uals with myeloma-associated Fanconi syndrome (lanes 2, 3, 5, and 6) or 10 ml of urine sample from a healthy control individual (lanes 1 and 4). 
Samples in lanes 1–3 were stained with silver nitrate and lanes 4–6 were subjected to immunoblotting with the anti-b2gpI antibody.
Demonstration of a Novel Receptor Recognition Site in b2-Glycoprotein-I 907
molecules in the liposomes decreases the functional receptor
affinity of b2gpI–PS complexes. In accordance with this obser-
vation, the inverse experiment (Fig. 7 B), where the PS con-
centration was constant and the b2gpI was varied, showed that
adding . 10 mg/ml b2gpI to 10 mg/ml PS or cardiolipin caused
an increase in binding.
b2gpI–PS binds to the high-affinity RAP binding site(s) in
megalin. RAP binds to multiple sites in the ligand-binding re-
gions of megalin. Previous SPR analysis (20) of the RAP bind-
ing to megalin showed that 50% of the RAP molecules dissoci-
ated rapidly after the receptors were saturated with RAP (20),
whereas the remaining 50% were almost irreversibly bound.
Fig. 8 (top curve) shows the binding of RAP and dissocia-
tion of z 50% of the RAP molecules. When b2gpI–PS subse-
quently was exposed to the megalin-RAP sensor chip, no sig-
nificant binding was seen in contrast to the binding seen to the
megalin-sensor chip without RAP (Fig. 8, bottom curve). This
demonstrates that the high-affinity bound RAP completely
blocks the megalin binding site(s) for b2gpI–PS.
Discussion
These data including investigation of mice with disrupted
megalin gene demonstrates megalin as an efficient and physio-
logical relevant receptor of b2gpI. Furthermore, we show that
binding of acidic phospholipids to b2gpI increases the func-
tional affinity in analogy with the stabilizing effect of lipid on
the receptor binding of apolipoproteins B and E.
b2gpI and kidney disease. Previous analyses of the urine
from patients suffering from renal tubule failure have shown
that b2gpI, compared with other known urinary proteins, is a
superior diagnostic marker for renal proximal tubule failure
seen after drug- or toxin-induced intoxication of renal tubules
and in a number of chronic diseases including adult Fanconi
syndrome, nephrocalcinosis associated with autoimmune dis-
eases, Lowe’s syndrome, and Dent’s disease (12, 35). 16 renal
proximal tubule failure patients in the study of Norden et al.
(12) excreted between 2 and 40 mg of b2gpI per millimole of
creatinine, whereas healthy controls had nondetectable amounts.
Previous data demonstrating b2gpI in the glomerular filtrate
of Bowman’s capsule (37) and the present data on megalin,
including absent renal uptake of b2gpI in megalin-deficient
mice, indicate that an insufficient activity of renal megalin
during renal proximal tubule failure causes the urinary excre-
tion of the ligand. The apparent high filtration rate of b2gpI is
remarkable in view of its size. The high content of basic amino
acids in b2gpI may in part account for this.
Using SPR for ligand screening. Although the present SPR
screening strategy identified a novel ligand, the screening as-
Figure 6. Binding of b2gpI–phospholipid 
complexes to megalin measured by SPR 
analysis. (A) Human b2gpI (10 mg/ml) and 
PS (10 mg/ml) were passed over a chip con-
taining purified megalin. (B) The maximal 
SPR response at flows with PS (10 mg/ml), 
cardiolipin (10 mg/ml), phosphatic acid 
(PA, 10 mg/ml), and phosphatidylcholine 
(PC, 10 mg/ml). All the curves and values 
displayed represent the response after sub-
traction of nonspecific binding, which was 
measured to a megalin chip inactivated by 
reduction.
Figure 7. SPR analysis of the binding of 
b2gpI–phospholipid to megalin at various 
concentrations of the protein and the phos-
pholipid. (A) Addition of various concen-
trations of PS to a constant concentration 
of b2gpI (10 mg/ml). (B) Addition of vari-
ous concentrations of b2gpI to a constant 
concentration of PS and cardiolipin (10 mg/
ml). Nonspecific binding was subtracted as 
described in the legend to Fig. 6.
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say was not successful in respect to identifying other megalin
ligands. This can partly be explained by the fact that ligands
with low plasma concentrations will not generate a measurable
SPR signal above background. Another problem is that pro-
tein fractions with very high amounts of abundant plasma pro-
teins such as albumin, which does not generate any SPR signal
itself, may mask the SPR signal generated by high affinity pro-
teins in much lower concentrations. Other methods for frac-
tionating serum, including removal of albumin before the ini-
tial SPR screening, are currently being evaluated in order to
improve the efficiency of the screening method.
Binding of phospholipid increases the functional affinity of
b2gpI. SPR analyses revealed that the phospholipids augment
the binding of b2gpI to megalin. In view of previous immu-
noreactivity and infrared spectroscopy studies (38), demon-
strating that binding to phospholipids causes a conformational
change of b2gpI, it is tempting to speculate that this neoconfor-
mation favors receptor binding. In this case the receptor recog-
nition site must be only partially cryptic, since megalin binds
and mediates endocytosis of the free form of b2gpI as well. Al-
ternatively, the binding of multiple b2gpI molecules associated
to each phospholipid vesicle may explain the increase in func-
tional affinity. The decreased binding observed, when very
high concentrations of PS were added (Fig. 7), does in fact in-
dicate this. A similar bonus effect of multivalency is suggested
for the binding of apolipoprotein E–containing lipoprotein
particles (39) and a2-macroglobulin–proteinase complexes
(28) to low density lipoprotein receptor–related protein.
b2gpI and clearance of PS-expressing cells and particles. It
is well established that surface expression of PS occurs in apop-
totic and senescent cells due to decreased activity of the ATP-
dependent aminophospholipid translocase (40) and several
mechanisms for PS-facilitated cellular recognition apparently
exist. A high density lipoprotein receptor related to scavenger
receptor I (41) and a microsialin/CD68 (42) have both been re-
ported to bind PS directly. However, recent data also suggest
an important role for b2gpI. b2gpI binds to rapidly cleared PS
liposomes (7) and to apoptotic thymocytes (43), and can in-
crease the uptake of erythrocyte ghosts and apoptotic thy-
mocytes in macrophages (6). The receptor in macrophages
must be different from megalin but in some of the megalin-
expressing epithelia, e.g., from the central nervous system
(ependyma), lung, yolk sac, intestine, and placenta as well as in
the ectoderm and neuroderm of the fetus, megalin may facili-
tate uptake of PS-containing particles.
In conclusion, this study has established the existence of a
novel physiological important receptor recognition site in
b2gpI. In addition to providing the molecular background for
the urinary excretion of b2gpI in patients suffering from renal
tubule failure, these data add further evidence for the function
of b2gpI as a linking molecule facilitating cellular uptake of PS-
exposing particles.
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